MarketCap
Facebook
X
Telegram
Accolade Income Statement 2024-2011 | ACCD
Brief overview of revenue and earnings at Accolade
The conclusions below are based on five years of reported results. The revenue attributed to Accolade moved from 94.8 million dollars to 414 million dollars between the two endpoints. Overall revenue changed by +337%, equal to an annualized rate of about 34.3%. The company expanded its revenue base at a high speed.
The gross result shifted from $34.2 million to $192 million, or +460.9%. Cost of revenue developed more favorably than sales, supporting gross profitability. Gross margin moved from 36.1% to 46.4%. Improving gross profitability strengthens the quality of revenue growth.
Over the period, EBITDA shifted from −44.6 million dollars to −69.3 million dollars, a change of −55.4%. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin was −47% at the start and −16.7% at the end. The increased EBITDA share is a positive sign.
The net financial result changed from −$56.5 million to −$99.8 million. Profitability deteriorated further over the five years.
Summary assessment
The results present an uneven picture without one dominant signal. The positive side is supported by sales growth, higher operating efficiency and a stronger gross margin. The main areas of concern are a low EBITDA margin and lower net income. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Accolade
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | - | 774 M | 245 M | - | - | - | - | - | - | - | - | - |
Shares |
74.9 M | 71.3 M | 63.8 M | 29.4 M | 5.63 M | 4.64 M | - | - | - | - | - | - | - | - |
Historical Prices |
- | - | - | 26.4 | 43.5 | - | - | - | - | - | - | - | - | - |
Net Income |
-99.8 M | -460 M | -123 M | -50.7 M | -51.4 M | -56.5 M | -61.3 M | - | - | - | - | - | - | - |
Revenue |
414 M | 363 M | 310 M | 170 M | 133 M | 94.8 M | 76.8 M | - | - | - | - | - | - | - |
Cost of Revenue |
222 M | 199 M | 169 M | 93.7 M | 73.7 M | 60.6 M | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | 58.8 M | 34.2 M | 23.4 M | - | - | - | - | - | - | - |
Operating Income |
-114 M | -464 M | -126 M | -46.8 M | -48.2 M | -54 M | - | - | - | - | - | - | - | - |
Interest Expense |
9.93 M | -15 K | -133 K | -147 K | -107 K | -90 K | - | - | - | - | - | - | - | - |
EBITDA |
-69.3 M | -417 M | -83.1 M | -38.6 M | -39.7 M | -44.6 M | -51.5 M | - | - | - | - | - | - | - |
Operating Expenses |
307 M | 628 M | 267 M | 123 M | 107 M | 88.2 M | 82.9 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
62.1 M | 81.2 M | 99.1 M | 31.6 M | 26.2 M | 19.7 M | 21.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Accolade
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
80.6 M | 80.1 M | 78.1 M | 80.6 M | 80.1 M | 78.1 M | 78.1 M | 76.1 M | 75.5 M | 73.2 M | 73.1 M | 71.2 M | 70.5 M | 69.7 M | 67.1 M | 65.4 M | 62.7 M | 61.3 M | 55.7 M | 51.6 M | 30.6 M | 33 M | 7.52 M | 5.78 M | 5.34 M | 4.95 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-121 M | -23.9 M | -27.6 M | -121 M | -23.9 M | -27.6 M | - | -21.1 M | -32.8 M | -38.4 M | - | -39.9 M | -46.5 M | -343 M | - | 22.5 M | -88.6 M | -48.7 M | -48.7 M | -16.6 M | -16.6 M | -15.4 M | -14 M | -18.3 M | -15 M | -15.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
105 M | 106 M | 110 M | 105 M | 106 M | 110 M | - | 99.4 M | 96.9 M | 93.2 M | - | 90.9 M | 87.6 M | 85.5 M | - | 83.4 M | 216 M | 133 M | 59.5 M | 38.4 M | 38.4 M | 36.8 M | 35.9 M | 29.7 M | 29.7 M | 28.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
58.6 M | 56.9 M | 58.6 M | 58.6 M | 56.9 M | 58.6 M | - | 54.5 M | 55.3 M | 54.2 M | - | 50.4 M | 49.8 M | 47.6 M | - | 45.2 M | 125 M | 80.3 M | 35.9 M | 22.7 M | 22.7 M | 21.1 M | 22.2 M | 17.5 M | 16.8 M | 17.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-122 M | -25.1 M | -29 M | -122 M | -25.1 M | -29 M | - | -31.7 M | -35.2 M | -39.6 M | - | -40.4 M | -45.9 M | -346 M | - | 26.5 M | -95.9 M | -122 M | -48 M | -16.5 M | -16.5 M | -12.9 M | -12.6 M | -17.4 M | -14.3 M | -15.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-69 K | -103 K | 94 K | -69 K | -103 K | 94 K | - | 9.28 M | 753 K | 390 K | - | 201 K | -130 K | -50 K | - | 25 K | -19 K | -44 K | -55 K | -42 K | -42 K | -104 K | -15 K | -18 K | -46 K | -34 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-91.2 M | -4.12 M | -18.7 M | -112 M | -14.5 M | -18.7 M | - | -20.3 M | -24.4 M | -28 M | - | -28.8 M | -34.3 M | -334 M | - | 37.8 M | -64.9 M | -103 M | -39.3 M | -14.4 M | -10.4 M | -8.92 M | -10.7 M | -15.4 M | -12 M | -13.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
169 M | 74.6 M | 80.9 M | 169 M | 74.6 M | 80.9 M | - | 76.6 M | 76.8 M | 78.7 M | - | 80.9 M | 83.7 M | 384 M | - | 11.7 M | 187 M | 175 M | 71.6 M | 32.2 M | 32.2 M | 28.6 M | 26.3 M | 29.6 M | 27.2 M | 26.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
16.2 M | 16.5 M | 16 M | 16.2 M | 16.5 M | 16 M | - | 15.5 M | 16.3 M | 16.1 M | - | 20 M | 21 M | 20.2 M | - | 21.5 M | 69.6 M | 48.2 M | 22 M | 8.41 M | 8.41 M | 6.45 M | 5.67 M | 8.55 M | 6.01 M | 5.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Accolade (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Akerna Corp.
KERN
|
- | - | $ 161 M |  USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
HealthEquity
HQY
|
$ 96.37 | 3.19 % | $ 8.3 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.53 | 0.57 % | $ 1.26 B | USA |
 |
Omnicell
OMCL
|
$ 33.08 | 0.15 % | $ 1.52 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 7.95 | 1.53 % | $ 148 M | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Progyny
PGNY
|
$ 26.0 | 0.54 % | $ 2.22 B | USA |
 |
10x Genomics
TXG
|
$ 61.54 | 0.92 % | $ 7.68 B | USA |
 |
Phreesia
PHR
|
$ 12.15 | 2.45 % | $ 726 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.92 | 20.44 % | $ 3.14 M |  China |
 |
Schrödinger
SDGR
|
$ 19.7 | 4.83 % | $ 1.45 B | USA |
 |
American Well Corporation
AMWL
|
$ 11.93 | 2.23 % | $ 191 M | USA |
 |
So-Young International
SY
|
$ 2.4 | 3.45 % | $ 187 M | China |
 |
Health Catalyst
HCAT
|
$ 1.59 | 1.57 % | $ 111 M | USA |
 |
HealthStream
HSTM
|
$ 29.38 | 1.91 % | $ 882 M | USA |
 |
Evolent Health
EVH
|
$ 4.6 | 0.22 % | $ 525 M | USA |
 |
Teladoc Health
TDOC
|
$ 6.5 | 2.12 % | $ 1.15 B | USA |
 |
Veeva Systems
VEEV
|
$ 276.69 | 0.83 % | $ 45.3 B | USA |